An ongoing phaseI/IIa trial (NCT05307874—EVICTION-2) testing the efficacy of ICT01 with low-dose IL-2 against advanced-stage solid tumors (including breast, ovarian, and colorectal cancer) has demonstrated the ability to reproducibly induce the activation and expansion of not onlyVγ9Vδ2 T cells, but also CD8+ T cells in 6/6 patients with relapsed/refractory ovarian and colorectal cancer. The gene discussed is CD8A; the disease is colorectal cancer.